)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
AnaptysBio (ANAB) investor relations material
AnaptysBio Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status Update summary14 Oct, 2025
Strategic and Company Structure Updates
Plans to separate into two independent public companies in 2026: one focused on biopharma R&D and commercialization, the other on royalty management.
The biopharma entity will advance therapeutics for autoimmune diseases, including ANB033 and rosnilimab.
The royalty management entity will manage rights to Jemperli (GSK) and Imsidolimab (Vanda), with minimal infrastructure.
Q2 2025 cash position is ~$294M, with expected runway through 2027, excluding significant royalty potential.
ANB033 Program Overview and Mechanism
ANB033 is a CD122 antagonist designed for high potency and dual inhibition of IL-15 and IL-2 signaling, targeting pathogenic immune cells in inflamed tissue.
Targets cytotoxic CD8+ T cells, memory CD4+ T cells, IELS, ILC2s, and NK cells, while sparing regulatory T cells.
Subcutaneous dosing achieves full receptor occupancy for over 30 days, with favorable pharmacokinetics and safety profile.
Demonstrated strong preclinical efficacy in models of GvHD and celiac disease, reducing cytolytic gene expression and preserving tissue integrity.
In EOE, ANB033 targets both CD4+ ILC2 and CD8+ NK cell pathways, potentially offering broader efficacy than current therapies.
Clinical Development and Trial Design
Phase 1a in healthy volunteers (n=60 ANB033, n=20 placebo) showed favorable safety, tolerability, and PK/PD profile, with no serious adverse events or discontinuations.
ANB033 significantly reduced CD122+ CD8+ T cells and NK cells after a single dose, with effects limited to CD122-expressing cells.
Phase 1b in celiac disease includes two cohorts: one for prevention of gluten-induced injury (Vh:Cd ≥2.0) and one for healing established mucosal damage (Vh:Cd <2.0), each enrolling 30 patients.
Primary endpoints include change in Vh:Cd ratio, IEL count, and patient-reported outcomes (CDSD), with results expected by year-end 2026.
Sites are located in Western EU, Australia, and New Zealand.
ANB033's differentiation vs. other CD122s?
Why two distinct cohorts for ANB033 P1b CeD?
What is the strategy for ANB033 in EoE?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AnaptysBio earnings date
Q3 20254 Nov, 2025
Next AnaptysBio earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
AnaptysBio Inc is a clinical-stage biotechnology company. It focuses on developing immunology therapeutics aimed at autoimmune and inflammatory diseases. The company's product pipeline includes several key antibody candidates like Imsidolimab, an anti-IL-36 receptor antibody for treating generalized pustular psoriasis, currently in Phase 3 trials. Another significant product is Rosnilimab, an anti-PD-1 agonist antibody designed to address T-cell driven inflammatory diseases. Additionally, ANB032, an anti-BTLA modulator antibody, is being developed for various human inflammatory diseases linked to immune cell dysregulation. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage